Subependymoma is a rare type of central nervous system tumor that develops from the ependymal cells that form the lining of the ventricles of the brain and the Central Canal. This form of tumor most often occurs in adults, but can also be diagnosed in children, especially during growth and development. Subependymoma is a low-grade tumor and most often presents with slowly progressive symptoms along with an increase in brain volume. Key symptoms may include headaches, visual disturbances, symptoms of increased intracranial pressure, and sensory and motor impairment. Treatment usually involves surgery to remove the tumor, which provides the best outcome, but monitoring the patient's condition is also important.
History of the disease and interesting historical facts
Subependymomas began to be actively studied and classified in the mid-20th century, when a system of histological diagnostics of brain tumors was developed. The first cases of this tumor were described in the relevant medical literature in the 1940-50s. Interesting facts coexist with the fact that in earlier times such tumors were often mistakenly classified as more aggressive forms - astrocytomas or other highly malignant neoplasms. In the 1970s, a unified approach to the diagnosis of subependymomas was formed, which takes into account their histological features and clinical manifestations. The modern approach to understanding this disease was facilitated by advances in neuroimaging, which allow for the accurate identification of such tumors.
Epidemiology
According to statistics, subependymomas account for 0.5% to 1.5% of all brain tumors. They are most common in adults aged 30 to 50 years, but can also occur in children, especially between the ages of 5 and 15 years. Most often, tumors are localized in the lateral ventricles of the brain. Studies show that subependymomas are diagnosed in men 1.5-2 times more often than in women. It is important to note that in a small percentage of cases, a link is observed between subependymoma and neurofibromatosis type II syndrome, which emphasizes the need for a more in-depth study of hereditary factors associated with the development of this disease.
Genetic predisposition to this disease
Some studies suggest a genetic predisposition to subependymomas, particularly in patients with neurofibromatosis. In particular, altered or mutated genes such as NF2 (the gene responsible for the development of neurofibromatosis) have been associated with an increased risk of developing tumors in the CNS. Importantly, subependymomas, like other tumors, may have genetic mutations that contribute to their occurrence and progression. However, in most cases, the specific molecular genetic mechanisms require further study to better understand the pathogenesis of this disease.
Risk factors for the development of this disease
The development of subependymoma may be associated with several risk factors, including:
- Inherited disorders such as neurofibromatosis type II.
- Exposure to ionizing radiation, such as from radiotherapy.
- External physical factors, including head injuries and their consequences.
- Chemical carcinogens, such as certain substances used in industrial settings.
- Unstudied environmental factors that may influence the tumor process.
Given that subependymomas are relatively rare, many of these factors require further research and do not have a clear statistical basis for definitive conclusions.
Diagnosis of this disease
Diagnosis of subependymoma begins with a thorough history and physical examination. The main symptoms include:
- Headaches that may worsen over time.
- Visual or hearing impairments.
- Symptoms of increased intracranial pressure, such as nausea and vomiting.
- Sensory and motor disorders that may affect one side of the body.
Laboratory tests may include blood tests, but they are not specific for the disease. Radiological examinations are the main diagnostic method and include:
- Magnetic resonance imaging (MRI), which allows visualization of the tumor and assessment of its boundaries.
- Computed tomography (CT) scan to obtain more detailed images in some cases.
Other diagnostics may include neuropsychological testing to assess cognitive function. Differential diagnosis is important to rule out other tumors such as astrocytomas or meningiomas.
Treatment
Treatment of subependymoma primarily depends on its size, location, and severity of symptoms. The main approaches include:
- Surgical treatment, which is the main method of treatment. Complete removal of the tumor provides the best chance of recovery.
- Pharmacological treatment, which may include pain relievers and steroids to reduce swelling.
- Radiotherapy may be considered in cases where complete removal is not possible or the tumor recurs.
- Monitoring patients with asymptomatic tumors to avoid unnecessary intervention.
A combination of different treatments may be used to achieve the best results.
List of medications used to treat this disease
The main groups of drugs that can be used in the treatment of subependymoma include:
- Pain relievers (eg, nonsteroidal anti-inflammatory drugs)
- Corticosteroids (eg, dexamethasone to reduce swelling)
- Antitumor drugs are used in case of relapse or metastasis
It should be emphasized that the choice of drug therapy remains at the discretion of the physician and is carried out individually.
Disease monitoring
Monitoring the patient's condition after treatment of subependymoma requires periodic observation to detect possible recurrences and assess long-term consequences. Control stages include:
- Regular MRI to assess the tumor status and signs of recurrence.
- Clinical examinations and assessments of neurological functions.
- Assessment of the patient's quality of life, including physical and psycho-emotional rehabilitation.
The prognosis in case of complete removal of the tumor is favorable, however complications such as neurological disorders or relapse of the disease are possible.
Age-related features of the disease
Subependymomas may present differently depending on the age of the patient. In children and adolescents, tumors are more often located in the third ventricle, while in adults, they are more often located in the lateral ventricles. Children may present more severe symptoms due to anatomical differences and ongoing growth of the systems, while adults may experience a longer asymptomatic course. It is important to consider these differences in diagnosis and treatment.
Questions and Answers
- What are the main symptoms of subependymoma? The most common symptoms include headaches, visual disturbances, increased intracranial pressure, and sensory disturbances.
- How is subependymoma diagnosed? Diagnosis is based on MRI, clinical examination and, if necessary, additional testing.
- Can subependymoma be malignant? Although subependymoma is usually considered a low-grade tumor, aggressive forms may be seen in rare cases.
- What treatments are available for patients with subependymoma? The main treatment methods include surgical removal, drug therapy and radiotherapy in case of recurrence.
- What is the prognosis for patients after treatment? If the tumor is successfully removed, the prognosis is usually good, but regular monitoring for possible recurrence is important.
